GenASIs offers automated pathology tissue analysis for primary diagnostics, generating reproducible and reliable results.
The FDA-cleared GenASIs platforms provide a comprehensive solution, allowing cytogeneticists, pathologists and technologists to focus on the clinical rather than the technical components.
ASI CEO Limor Shiposh said the introduction of new GenASIs platforms and product suite will allow them to further strengthen their market presence and establish ASI as the leader in image acquisition and analysis worldwide for the cytogenetic and pathology markets.
”Our ongoing success is built on setting new industry standards of quality, reliability and service with our GenASIs offering,” Shiposh added.
